Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Danish pharmaceutical company Novo Nordisk on Tuesday launched its once-weekly injectable weight-loss drug Wegovy in India, at Rs 4,336.25 per dose. Wegovy, a once-weekly glucagon-like peptide-1 ...

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...

Novo Nordisk launches weightloss drug Wegovy in India at competitive prices, facing patent battles and high demand.

Danish pharma giant Novo Nordisk on Tuesday launched its blockbuster weight loss drug Wegovy as a once-a-week injection in ...

Danish company Novo Nordisk has launched Wegovy, its once-weekly weight-loss injection, in India as of June 24, 2025.

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's ...